Abstract
A total of 202 evaluable cancer patients were randomly assigned to receive or not receive oral clotrimazole as antifungal prophylaxis during hospitalization. Oropharyngeal candidiasis occurred in 1% of the former patients and 27% of the latter patients (P < .00001). Candida sp were cultured from the initial throat specimens of 53 control patients and 55 patients who received prophylaxis. Oropharyngeal candidiasis subsequently developed in 2% of the former patients and 38% of the latter patients (P = <.00001). Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1668-1671 |
| Number of pages | 4 |
| Journal | Journal of Clinical Oncology |
| Volume | 3 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1985 |
ASJC Scopus subject areas
- Oncology
- Cancer Research